Drugs / AZD0585
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02372344 | Mar → May 2015 | — | AstraZeneca | Completed | Mixed |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02463071 | Jun 2015 → Mar 2017 | hypertriglyceridemia | AstraZeneca | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02463071 ↗ |
| Route | Oral | “Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4.” NCT02372344 ↗ |